The follow-on decision: how a fund doubles down

Interviewer: This one's almost the opposite of last time. A company's doing well, it's raising a new round, and you have to decide whether to put in more. That sounds like the easy, happy version. Is it?

Partner: [laughs] Everyone thinks that. "Oh, the company's crushing it, of course you write the check." It is genuinely one of the hardest, least-disciplined decisions in the whole job. And the reason is it feels easy, so people don't actually think about it — they just reflexively do their pro-rata because it feels good to back a winner. And that reflex costs funds a fortune.

Interviewer: Okay, back up. There's this word "reserves." Set the table for me.

Partner: Right. So when we make an initial investment — say we put two million into a seed — we don't just spend the two million and move on. We mentally, and in our model literally, set aside more capital for that company. "We've invested two, we're reserving another four for follow-ons." Across the whole fund you're constantly holding back this pool of dry powder for your existing companies. The mistake people make is they think of reserves as set-and-forget. They're not. They're alive, they're constantly competing, and that's the whole drama of this process.

Interviewer: So walk me through it from the moment a company says it's raising.

Partner: So the trigger is the company tells you they're raising the next round — or sometimes someone pre-empts, a big fund swoops in and says "we want to lead your Series B" before they were even planning to raise. First thing, I get the terms. What's the new valuation? How big's the round? Who's leading it? And critically — what's my allotment, my pro-rata, the amount I'm contractually allowed to put in to maintain my ownership. That number frames everything.

Interviewer: And then you just decide if you want it?

Partner: No — first I have to do real work, and this is the step people rush. I go back to the original thesis. What did we actually bet on when we wrote that first check? And is that thing happening? Because sometimes a company looks great on the surface — revenue's up, logos are great — but the specific thing you believed, the reason this was going to be a monster, that thing died and got replaced by a fine-but-not-special business. So I refresh against the original bet, then I gather the current data — the metrics, the board materials, burn, growth rate, retention, all of it.

Interviewer: And from that you re-score it?

Partner: I re-underwrite it. Like it's a brand new investment. And the question is not "is this a good company" — lots of good companies. The question is: is this still a fund-returner? Can this single position pay back my entire fund? Because that's the only kind of company that deserves more of my limited reserves. A solid 3x company is nice, but a follow-on dollar into a solid 3x might be a worse use of capital than holding that dollar for the next potential 50x. That's the lens.

Interviewer: Then what — the ownership stuff?

Partner: Then the math. What do I own now, what does pro-rata keep me at, and — this is the part that stings — what happens to my ownership if I don't play? Because if I sit out, I get diluted. The new round comes in, my percentage drops. So passing isn't neutral, passing is actively giving up ownership in a company I believe in. You have to feel that cost.

Interviewer: You mentioned signals last time too. Is there a signal read here?

Partner: Two, actually. First, the round quality itself. Is this a strong, priced up-round led by a great new outside investor? That's a positive signal — somebody smart did fresh diligence and is paying up. Versus a soft round, an insider round where the existing investors are basically propping up the valuation because no new lead showed up. That tells you something very different, even if the headline number looks fine. And second — and this is the sneaky one — my own signal. What does it say to the market and to the founder if I, the investor who's known this company longest, don't take my pro-rata? It can read as "her own early backer passed — what does she know that we don't?" So sometimes you follow on partly to avoid sending a negative signal, which, by the way, is a slightly toxic reason to invest and you have to be honest with yourself about when you're doing that.

Interviewer: So now you know what you'd like to do. What stops you?

Partner: Reality, in the form of dry powder. I check what's actually left in reserves and — here's the thing — there are competing claims on it. I don't have one company raising. I might have three companies all hot, all raising in the same six months, all wanting me to lean in, and I do not have enough reserve for all of them to go big. So this decision is never standalone. It's always against the others.

Interviewer: How do you compare them?

Partner: I model the outcome. Under a few scenarios — base, good, home-run — what's my ownership at exit, and what's the return on the marginal dollar? That phrase matters: not "is this company good," but "is the next dollar I put in this company going to return more than that same dollar somewhere else?" And "somewhere else" includes a brand new investment I haven't made yet, or holding it for one of those other two hot companies. That's the opportunity-cost step, and it's where the real discipline lives.

Interviewer: Okay, and now the actual decision.

Partner: Now the central fork. And it's not yes/no, it's a menu of postures. I can pass — take the dilution, sit it out. I can do my pro-rata — maintain my ownership, the default. I can go super pro-rata — lean in, buy more than my share, increase my ownership because I'm so convicted. Or I can do a bridge-only kind of move in some cases. And picking which posture is the whole art. Super pro-rata into your eventual fund-returners is, statistically, where a huge amount of venture returns actually come from — not the initial checks, the doubling down on the winners. But you have to be right, because super pro-rata into something that turns out mediocre is a great way to drag your whole fund down.

Interviewer: Say you decide to lean in. Super pro-rata.

Partner: Then there's a sub-decision: do I just want to follow, or do I actually want to lead or co-lead this new round? Leading means more ownership, maybe a board seat, more control — but it's also more work and more concentration risk. Versus if I decide to pass, the work isn't zero either — I have to actually manage that conversation with the founder so it doesn't blow up the relationship or send that bad signal we talked about. "Here's why we're not leading this one" — said carefully.

Interviewer: And then I assume there's red tape.

Partner: There's always red tape, and it's there for good reasons. I have to check the fund's constraints. Concentration limits — am I allowed to have this much of the fund in one company? Ownership caps. Recycling rules, fund-life questions, sometimes you need to clear it with the LP advisory committee. These are the guardrails that stop a partner from going all-in on their pet company. Then, assuming I'm clear, I actually allocate the capital from the reserve pool — I draw it down and I re-earmark what's left.

Interviewer: And sign-off, like last time?

Partner: Same as the save-or-kill, it goes to the partnership, the IC. And they can approve it, they can size it down — "do half of what you're asking" — or they can decline. Sizing-down is common, actually, it's the IC imposing portfolio-level discipline on an excited partner. Then if it clears, we execute — sign, wire, update the cap table.

Interviewer: And that's the end?

Partner: No — and this is the step that I think separates firms that are good at this from firms that just react. After it's done, I update the ownership tracker and, crucially, I rebalance the remaining reserves across the entire rest of the portfolio. Because here's the thing nobody internalizes: every yes is a no somewhere else. The four million I just put into this winner is four million that's no longer available for the other twenty companies. So allocating to one silently re-prices the reserve I'm holding for everyone else. If I just keep saying yes to whoever's raising next, I'll run out of reserves right before my best company raises its biggest, most important round. So the portfolio-level rebalance isn't optional, it's the actual job.

Interviewer: And then?

Partner: And then I set the next review trigger and the whole thing loops. Because that company's going to raise again in eighteen months, and I'll be right back at the top of this process — re-underwriting, re-checking reserves, re-deciding posture — except now with even more money at stake and even more emotional attachment. It just keeps going until the company exits or dies.

Interviewer: If you had to name the one thing firms get wrong here — same question as last time.

Partner: The opportunity-cost step. Number eleven, twelve, whatever you called it. People evaluate the follow-on in isolation — "is this company worth more money?" — and the answer's almost always yes, because it's a winner, of course it's worth more money. But that's the wrong question. The right question is "is this dollar better here than anywhere else in or out of my portfolio?" Firms that ask the first question deploy all their reserves into the good companies and have nothing left for the great one. Firms that ask the second question end up concentrated in their winners. And over a ten-year fund, that single difference in how you frame the question is most of the gap between a top-quartile fund and a mediocre one.

Interviewer: That's a great place to end. Thank you.

Partner: My pleasure. This one's more fun than the funerals. [laughs]